drugset / Trial / NCT00023959
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
NaSingle-groupOpen-labelTreatment
Summary
Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining monoclonal antibody therapy with chemotherapy and radiation therapy may be an effective treatment for head and neck cancer. This phase I trial is to see if combining bevacizumab, fluorouracil, and hydroxyurea with radiation therapy works in treating patients who have advanced head and neck cancer
Timeline
- Start
- 2001-07
- Primary completion
- 2010-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Background | Hydroxyurea | Other / unclassified | — | Oral |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |
| Background | fluorouracil | Small molecule | — | Intravenous |
Indications
adenoid cystic carcinoma
esthesioneuroblastoma
hypopharynx squamous cell carcinoma
intraoral basal cell carcinoma
inverted papilloma
larynx verrucous carcinoma
lymphoepithelial-like carcinoma
metastatic squamous cell carcinoma
nasal cavity and paranasal sinus lethal midline granuloma
nasal cavity and paranasal sinus squamous cell carcinoma
nasopharyngeal squamous cell carcinoma
oral cavity mucoepidermoid carcinoma
oropharynx squamous cell carcinoma
salivary gland cancer
verrucous carcinoma of oral cavity